-
Pfizer submitted an application to the FDA for an upgraded vaccine for people aged 5 to 11 years
Time of Update: 2022-10-01
(End) Pfizer submitted an application authorization to the US Food and Drug Administration (FDA) on the 26th local time for the vaccination of Pfizer upgraded version of the new crown vaccine for groups aged 5 to 11.
-
30 billion market Livzon "Fengwang" collection variety "big dive"
Time of Update: 2022-10-01
Recently, through the 2022 medical insurance preliminary review of the drug list released to the public, this year's medical insurance catalog adjustment work has entered a critical period, and vario
-
US experts: The new crown epidemic is not over It is irresponsible to play down the epidemic
Time of Update: 2022-10-01
According to a survey report released by the US Center for Disease Control and Prevention in June this year, nearly one in five adults who have been infected with the new crown virus and tested negative still have some symptoms, including fatigue, tachycardia, shortness of breath, cognitive difficulties, chronic pain, abnormal sensory function, muscle weakness and so on.
-
The revenue of the whole industrial chain of Jiangxi Zhangshu Traditional Chinese Medicine reached 108.1 billion yuan
Time of Update: 2022-10-01
(End) On the 22nd, the reporter learned from the press conference of the 53rd National Medicinal Materials and Drugs Fair of Zhangshu that the operating income of the whole industry chain of traditional Chinese medicine planting, production and circulation in Jiangxi Zhangshu, the "medicine capital", reached 108.
-
Two departments: relying on the emergency general hospital to establish a national pneumoconiosis diagnosis and treatment center
Time of Update: 2022-10-01
Hospitals According to the website of the Ministry of Emergency Management, the Ministry of Emergency Management recently issued a notice on the establishment of a national pneumoconiosis diagnosis and treatment center, and the National Health Commission agreed to rely on the emergency general hospital to establish a national pneumoconiosis diagnosis and treatment center.
-
China's multi-level social security system has been continuously improved and remarkable results have been achieved in the work on the elderly
Time of Update: 2022-10-01
The National Health Commission held a press conference today (September 20) to introduce the progress and achievements of the work on aging since the 18th National Congress of the Communist Party of China.
-
1.03 billion people participate in basic endowment insurance nationwide Basic medical insurance covers 1.36 billion people
Time of Update: 2022-10-01
On the morning of September 20, the National Health Commission held a press conference to introduce the progress and results of the work on the elderly since the 18th National Congress of the Communi
-
Jichuan Pharmaceutical's 2 billion single products withdraw from medical insurance, which may affect the use of raw materials!
Time of Update: 2022-10-01
。 Fourth, Pu Di blue anti-inflammatory oral liquid raw material market reviews dandelion, low-priced varieties, planting area is not large, coupled with this year's wild production areas such as Gansu and other places suffered drought, limited output, early price rise, recently there are bulk supply transactions, merchants actively sell, the market is running firmly, the spot wild goods price in 13-14 yuan (kg price, the same below), the home breeding goods merchants shouted price of 7.
-
API companies are competing to expand production capacity, and pharmaceutical machinery companies are ushering in a good opportunity for development
Time of Update: 2022-09-30
API enterprises are vying to expand production capacity, and pharmaceutical machinery enterprises are ushering in a good opportunity for development (Source: Pharmaceutical Network) The second phase of the project will build a new drug packaging material production line, targeted anti-tumor drug production line and related supporting facilities.
-
Today, Zixin Pharmaceutical, Shuangcheng Pharmaceutical and many other individual stocks rose and stopped!
Time of Update: 2022-09-30
It is understood that Zixin Pharmaceutical has risen and stopped 7 times in the past year.
It is understood that Zixin Pharmaceutical has risen and stopped 7 times in the past year.
It is understood that Zixin Pharmaceutical has risen and stopped 7 times in the past year.
-
With low clinical trial success rate and low use efficiency, how to break through the bottleneck of "double low" new drug research and development?
Time of Update: 2022-09-30
(Image source: pharmaceutical network) New drug research and development is facing a "double low" bottleneck In terms of drug clinical trials, with the continuous increase in R&D investment of domestic pharmaceutical companies, although there are many candidates for clinical trials, the proportion of candidates who can survive to successful approval for listing is not large.
-
The dust has settled! The third batch of collection in Zhejiang Province does not involve growth hormone, and related concept stocks have risen slightly
Time of Update: 2022-09-30
On August 17, the news that "Zhejiang Province will carry out growth hormone collection" was reported on the Internet, although it was a false shot, but the Changchun high-tech stock price still fell to a halt on that day, closing at 202.
-
High-end preparation technology has become an important breakthrough point in domestic pharmaceutical innovation, and 2 major "short boards" have yet to be filled
Time of Update: 2022-09-30
At present, many domestic pharmaceutical companies, including Qilu Pharmaceutical and Ruihua Pharmaceutical, have continued to increase R&D investment in the field of new high-end preparations, and have gradually built a series of preparation research and development and production platforms, constantly breaking through the "card neck" technology and achieving rapid transformation of scientific research results.
-
Another pharmaceutical stock is advancing into the "A+H" era!
Time of Update: 2022-09-30
According to the 2022 semi-annual report, the total revenue of Nuocheng Jianhua in the first half of 2022 was 246 million yuan, up 142% year-on-year, of which the sales volume of obufixib after it was included in medical insurance increased by 115% year-on-year.
-
In order to achieve high-quality development, the traditional Chinese medicine industry is accelerating the combination of digitalization
Time of Update: 2022-09-30
In recent years, "digitalization" has become more and more familiar to people, and it is increasingly used in different fields. Relevant people in the industry believe that in the high-quality develop
-
The PD-1 track "inner roll" is still intensifying!
Time of Update: 2022-09-30
Xindilimumab According to the disclosure of Lilly, due to the impact of medical insurance price cuts, the epidemic and the adjustment of the company's commercialization team, the sales revenue of Daboshu (Xindilizumab injection) of Cinda Bio in the first half of 2022 was US$159 million, a year-on-year decrease of 26% compared with the same period last year.
-
Under the frequent favorable policies, the Chinese medicine sector continued to strengthen, with one stock rising more than 15%
Time of Update: 2022-09-30
【Pharmaceutical Network Pharmaceutical Stock Market】On September 28, the Chinese medicine sector rose unexpectedly, of which Enwei Pharmaceutical rose rapidly in the intraday, rising more than 2% in 5
-
The New Deal encourages the continuous manufacture of oral solid formulations or creates opportunities upstream
Time of Update: 2022-09-30
The Draft for Comments elaborates on the overall considerations, related concepts, control strategies, process verification, stability studies, batch changes, drug quality systems, and declaration data requirements for the continuous manufacturing of oral solid preparations of chemical drugs, and aims to provide guidance for the research and evaluation of continuous manufacturing technology of oral solid preparations of chemical drugs.
-
The next city for 10 billion drugs: NASH drugs
Time of Update: 2022-09-30
On the evening of September 22, China Biopharmaceutical announced that Chia Tai Tianqing, a subsidiary of the company, signed an agreement with the French Inventiva (IVA) company to obtain the exclusive licensing rights of the IVA treatment of non-alcoholic steatohepatitis treatment drug lanifibranor in Greater China, and the drug was certified by the US FDA as a "breakthrough therapy".
-
Today, 2 pharmaceutical companies are listed on the market, starting a new journey
Time of Update: 2022-09-30
According to the data, Enwei Pharmaceutical is mainly engaged in the research and development, production and sales of proprietary Chinese medicines and chemical drugs, focusing on gynecological products, pediatric drugs, respiratory system drugs and other fields.
